CA
NZ
UK
AU
IND
US
…
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -1.41M | -0.46M | -0.79M | -0.69M | -1.03M |
| Net income | -1.41M | -0.46M | -0.80M | -0.68M | -1.03M |
| Selling general administrative | 0.92M | 1.34M | 1.28M | 1.24M | 1.41M |
| Selling and marketing expenses | 0.14M | 0.30M | 0.49M | 0.46M | 0.55M |
| Gross profit | -0.19M | 0.55M | 1.24M | 1.18M | 1.29M |
| Reconciled depreciation | 0.05M | 0.07M | 0.08M | 0.08M | 0.08M |
| Ebit | -1.24M | -1.18M | -0.70M | -0.67M | -0.84M |
| Ebitda | -1.16M | -0.43M | -0.62M | -0.59M | -0.76M |
| Depreciation and amortization | 0.08M | 0.74M | 0.08M | 0.08M | 0.08M |
| Non operating income net other | - | - | -0.17M | -0.09M | -0.26M |
| Operating income | -1.24M | -1.18M | -0.62M | -0.59M | -0.76M |
| Other operating expenses | 2.25M | 3.40M | 4.77M | 4.25M | 4.63M |
| Interest expense | 0.19M | 0.19M | 0.17M | 0.27M | 0.28M |
| Tax provision | 0.00M | 0.00M | 0.00M | -0.01M | 0.00M |
| Interest income | 0.00M | - | - | 0.00M | 0.00M |
| Net interest income | -0.19M | -0.19M | -0.17M | -0.27M | -0.28M |
| Income tax expense | 0.00M | 0.00M | 0.00M | -0.01M | 0.00M |
| Total revenue | 0.91M | 2.22M | 4.15M | 3.65M | 3.87M |
| Total operating expenses | 1.14M | 1.73M | 1.86M | 1.78M | 2.05M |
| Cost of revenue | 1.11M | 1.67M | 2.91M | 2.47M | 2.58M |
| Total other income expense net | -0.17M | 0.72M | -0.17M | -0.09M | -0.26M |
| Net income from continuing ops | -1.41M | -0.46M | -0.80M | -0.68M | -1.03M |
| Net income applicable to common shares | -1.41M | -0.46M | -0.80M | -0.68M | -1.03M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1.27M | 1.88M | 1.93M | 2.08M | 2.48M |
| Intangible assets | - | - | 0.11M | 0.12M | 0.12M |
| Other current assets | 0.07M | 0.06M | 0.14M | 0.04M | 0.03M |
| Total liab | 3.61M | 2.83M | 3.18M | 2.87M | 2.62M |
| Total stockholder equity | -2.34M | -0.94M | -1.26M | -0.79M | -0.15M |
| Other current liab | 0.61M | 0.51M | 0.56M | 0.64M | 0.70M |
| Common stock | 0.48M | 0.48M | 0.38M | 0.33M | 0.32M |
| Capital stock | 0.48M | 0.48M | 0.38M | 0.33M | 0.32M |
| Retained earnings | -25.22M | -23.81M | -23.35M | -22.55M | -21.87M |
| Other assets | 0.02M | 0.02M | 0.02M | -0.00M | 0.02M |
| Cash | 0.03M | 0.12M | 0.10M | 0.00M | 0.11M |
| Total current liabilities | 3.60M | 2.82M | 2.02M | 1.69M | 1.82M |
| Current deferred revenue | - | 0.05M | 0.17M | 0.01M | 0.03M |
| Net debt | 2.21M | 1.47M | 1.78M | 1.56M | 1.42M |
| Short term debt | 2.23M | 1.58M | 0.72M | 0.39M | 0.74M |
| Short long term debt | 2.23M | 1.54M | 0.68M | 0.35M | 0.74M |
| Short long term debt total | 2.24M | 1.58M | 1.88M | 1.57M | 1.53M |
| Other stockholder equity | 22.40M | 22.39M | 21.72M | 21.44M | 21.40M |
| Property plant equipment | 0.48M | 0.52M | 0.58M | 0.72M | 0.72M |
| Total current assets | 0.77M | 1.34M | 1.18M | 1.23M | 1.61M |
| Net tangible assets | -2.34M | -0.94M | -1.36M | -0.91M | -0.27M |
| Net receivables | 0.28M | 0.72M | 0.41M | 0.37M | 0.45M |
| Long term debt | - | - | 1.12M | 1.11M | 0.79M |
| Inventory | 0.38M | 0.44M | 0.54M | 0.81M | 1.02M |
| Accounts payable | 0.76M | 0.68M | 0.58M | 0.65M | 0.36M |
| Common stock total equity | - | - | 0.38M | 0.33M | 0.32M |
| Retained earnings total equity | - | - | -23.35M | -22.55M | -21.87M |
| Non currrent assets other | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Non current assets total | 0.50M | 0.54M | 0.75M | 0.85M | 0.86M |
| Capital lease obligations | 0.01M | 0.04M | 0.07M | 0.11M | - |
| Long term debt total | - | - | 1.12M | 1.11M | 0.79M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | 0.00M | -0.00M | 0.00M | -0.02M |
| Change to liabilities | 0.08M | 0.10M | -0.03M | 0.21M | 0.14M |
| Total cashflows from investing activities | - | - | -0.00M | -0.00M | -0.02M |
| Net borrowings | 0.69M | 0.59M | 0.38M | -0.17M | 0.12M |
| Total cash from financing activities | 0.69M | 0.69M | 0.58M | -0.17M | 0.32M |
| Change to operating activities | 0.19M | -0.48M | -0.02M | -0.06M | 0.25M |
| Net income | -1.41M | -0.46M | -0.80M | -0.68M | -1.03M |
| Change in cash | -0.08M | 0.02M | 0.09M | -0.11M | 0.08M |
| Begin period cash flow | 0.12M | 0.10M | 0.00M | 0.11M | 0.04M |
| End period cash flow | 0.03M | 0.12M | 0.10M | 0.00M | 0.11M |
| Total cash from operating activities | -0.77M | -0.67M | -0.48M | 0.06M | -0.22M |
| Issuance of capital stock | 0.00M | 0.10M | 0.20M | 0.00M | 0.20M |
| Depreciation | 0.05M | 0.07M | 0.08M | 0.08M | 0.08M |
| Other cashflows from investing activities | - | - | - | - | -0.02M |
| Change to inventory | 0.11M | 0.09M | 0.12M | 0.11M | 0.32M |
| Change to account receivables | 0.24M | 0.10M | -0.04M | 0.08M | -0.09M |
| Sale purchase of stock | - | - | 0.20M | - | 0.20M |
| Other cashflows from financing activities | 1.86M | 2.83M | 4.43M | 3.92M | 4.28M |
| Change to netincome | -0.03M | -0.10M | 0.01M | 0.00M | -0.01M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.02M |
| Change receivables | - | - | -0.04M | 0.08M | -0.09M |
| Cash flows other operating | - | - | 0.16M | 0.14M | 0.23M |
| Cash and cash equivalents changes | - | - | 0.09M | -0.11M | 0.08M |
| Change in working capital | 0.62M | -0.18M | -0.02M | 0.43M | 0.47M |
| Stock based compensation | - | 0.00M | 0.00M | 0.01M | 0.01M |
| Other non cash items | -0.03M | -0.10M | 0.09M | 0.12M | 0.13M |
| Free cash flow | -0.77M | -0.67M | -0.49M | 0.06M | -0.24M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-12.18 1.72% |
697.00 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-4.75 2.00% |
232.23 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.73 3.01% |
23.56 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
| Name | Title | Year Born |
|---|---|---|
| Ms. Melissa A. Waterhouse | CEO, Principal Accounting & Financial Officer and Director | 1971 |
| Ms. Jean Neff | Corp. Sec. & Independent Director | 1943 |
| Mr. J. Duncan Urquhart | Controller | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...